Platelet utilization: A canadian blood services research and development symposium

Transfusion Medicine Reviews

Volumn 28, Issue 2, 2014, Pages 84-97

  Webert, Kathryn E ^a,b   Alam, Asim Q ^c,d   Chargé, Sophie B ^a   Sheffield, William P ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOSOME;

ALLOIMMUNIZATION; APHERESIS; AUSTRALIA; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CANADA; DRUG DELIVERY SYSTEM; ENVIRONMENTAL TEMPERATURE; HEMOSTASIS; HUMAN; INJURY; MEDICAL RESEARCH; NANOMEDICINE; NONHUMAN; PATIENT CARE; PLATELET ALLOIMMUNIZATION; REVIEW; SEPTIC TRANSFUSION REACTION; SYMPOSIUM; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; UNITED KINGDOM; BACTERIAL INFECTIONS; BLOOD BANK; BLOOD STORAGE; CHEMISTRY; CLINICAL TRIAL (TOPIC); CYTOLOGY; INTERNATIONAL COOPERATION; MICROBIOLOGY; PROCEDURES; SEPSIS; VIROLOGY;

BACTERIAL INFECTIONS; BLOOD BANKS; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD TRANSFUSION; CANADA; CLINICAL TRIALS AS TOPIC; HUMANS; INTERNATIONAL COOPERATION; LIPOSOMES; PLATELET TRANSFUSION; SEPSIS;

EID: 84899472269     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.01.002     Document Type: Review

References (95)

1. Sheffield W.P., Tinmouth A., Branch D.R. Blood group biochemistry: a Canadian Blood Services research and development symposium. Transfus Med Rev 2005, 19:295-307.
2. Tinmouth A.T., Semple E., Shehata N., et al. Platelet immunopathology and therapy: a Canadian Blood Services research and development symposium. Transfus Med Rev 2006, 20:294-314.
3. Shehata N., Lin Y., Pendergrast J., et al. Cellular therapies: a Canadian Blood Services research and development symposium. Transfus Med Rev 2007, 21:317-336.
4. Lin Y., Pavenski K., Saidenberg E., et al. Blood group antigens and normal red blood cell physiology: a Canadian Blood Services research and development symposium. Transfus Med Rev 2009, 23:292-309.
5. Saidenberg E., Petraszko T., Semple E., et al. Transfusion-related acute lung injury (TRALI): a Canadian Blood Services research and development symposium. Transfus Med Rev 2010, 24:305-324.
6. Pavenski K., Saidenberg E., Lavoie M., et al. Red blood cell storage lesions and related transfusion issues: a Canadian Blood Services research and development symposium. Transfus Med Rev 2012, 26:68-84.
7. Semple J.W., Italiano J.E., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011, 11:264-274.
8. Vlaar A.P., Juffermans N.P. Transfusion-related acute lung injury: a clinical review. Lancet 2013, 382:984-994.
9. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869.
10. Jackman R.P., Deng X., Bolgiano D., et al. Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants. Blood 2013, 121:3261-3266.
11. Asano H., Lee C.Y., Fox-Talbot K., et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007, 84:1174-1182.
12. Slichter S.J., Deeg H.J., Kennedy M.S. Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets. Blood 1987, 69:414-418.
13. Jackman R.P., Muench M.O., Heitman J.W., et al. Immune modulation and lack of alloimmunization following transfusion with pathogen-reduced platelets in mice. Transfusion 2013, 10.1111/trf.12133.
14. Ness P.M., Campbell-Lee S.A. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol 2001, 8:392-396.
15. Brecher M.E., Yomtovian R., Blajchman M.A., et al. Open letter to the blood collection community. ABC Newsl 2002, 33:18.
16. Brecher M.E., Yomtovian R., et al. Addressing the risk of bacterial contamination of platelets within the United States: a history to help illuminate the future. Transfusion 2013, 53:221-231.
17. Tobian A.A., King K.E., Ness P.M. Prevention of febrile nonhemolytic and allergic transfusion reactions with pretransfusion medication: is this evidence-based medicine?. Transfusion 2008, 48:2274-2276.
18. Tobian A.A., Savage W.J., Tisch D.J., et al. Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction. Transfusion 2011, 51:1676-1683.
19. Azuma H., Hirayama J., Akino M., et al. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol). Transfusion 2009, 49:214-218.
20. Slichter S.J., Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978, 7:523-539.
21. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997, 337:1870-1875.
22. Murthi S.B., Stansbury L.G., Dutton R.P., et al. Transfusion medicine in trauma patients: an update. Expert Rev Hematol 2011, 4:527-537.
23. Borgman M.A., Spinella P.C., Perkins J.G., et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma 2007, 63:805-813.
24. Levi M., Fries D., Gombotz H., et al. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox Sang 2011, 101:154-174.
25. Snyder C.W., Weinberg J.A., McGwin G., et al. The relationship of blood product ratio to mortality: survival benefit or survival bias?. J Trauma 2009, 66:358-362. [discussion 62-4].
26. Ho A.M., Dion P.W., Yeung J.H., et al. Prevalence of survivor bias in observational studies on fresh frozen plasma:erythrocyte ratios in trauma requiring massive transfusion. Anesthesiology 2012, 116:716-728.
27. Nascimento B., Callum J., Rubenfeld G., et al. Clinical review: fresh frozen plasma in massive bleedings-more questions than answers. Crit Care 2010, 14:202.
28. Dzik W.H., Blajchman M.A., Fergusson D., et al. Clinical review: Canadian National Advisory Committee on Blood and Blood Products-Massive transfusion consensus conference 2011: report of the panel. Crit Care 2011, 15:242.
29. Murphy S., Gardner F.H. Room temperature storage of platelets. Transfusion 1976, 16:2-3.
30. Murphy S., Gardner F.H. Effect of storage temperature on maintenance of platelet viability-deleterious effect of refrigerated storage. N Engl J Med 1969, 280:1094-1098.
31. Nessen S.C., Eastridge B.J., Cronk D., et al. Fresh whole blood use by forward surgical teams in Afghanistan is associated with improved survival compared to component therapy without platelets. Transfusion 2013, 53(Suppl. 1):107S-113S.
32. Pidcoke H.F., McFaul S.J., Ramasubramanian A.K., et al. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time. Transfusion 2013, 53(Suppl. 1):137S-149S.
33. Wandall H.H., Hoffmeister K.M., Sorensen A.L., et al. Galactosylation does not prevent the rapid clearance of long-term, 4 degrees C-stored platelets. Blood 2008, 111:3249-3256.
34. Stanworth S.J., Dyer C., Choo L., et al. Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions. Transfus Med Rev 2010, 24:163-171.
35. Stanworth S.J., Estcourt L.J., Powter G., et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013, 368:1771-1780.
36. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
37. Wandt H., Schaefer-Eckart K., Wendelin K., et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012, 380:1309-1316.
38. Wandt H., Schafer-Eckart K., Ehninger G. Prophylactic platelet transfusion. N Engl J Med 2013, 369:577.
39. Slichter S.J. Prophylactic platelet transfusion. N Engl J Med 2013, 369:577-578.
40. Field M.J., Lohr K.N. Health services research: an expanding field of inquiry. J Eval Clin Pract 1995, 1:61-65.
41. Wollersheim H., Burgers J., Grol R. Clinical guidelines to improve patient care. Neth J Med 2005, 63:188-192.
42. Pavenski K., Rebulla P., Duquesnoy R., et al. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013, 53:2230-2242.
43. Vassallo R.R., Fung M., Rebulla P., et al. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013, 10.1111/trf.12395.
44. Kerkhoffs J.L., Eikenboom J.C., van de Watering L.M., et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008, 48:1959-1965.
45. Rebulla P. A mini-review on platelet refractoriness. Haematologica 2005, 90:247-253.
46. Doughty H.A., Murphy M.F., Metcalfe P., et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
47. Rebulla P. Refractoriness to platelet transfusion. Curr Opin Hematol 2002, 9:516-520.
48. Slichter S.J., Bolgiano D., Kao K.J., et al. Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products. Transfus Med Rev 2011, 25:102-110.
49. Vassallo R.R., Hsu S., Einarson M., et al. A comparison of two robotic platforms to screen plateletpheresis donors for HLA antibodies as part of a transfusion-related acute lung injury mitigation strategy. Transfusion 2010, 50:1766-1777.
50. Petz L.D. The HLA system: basic biology and clinical implications 1999, AABB Press, Bethesda, MD. S. Murphy (Ed.).
51. Duquesnoy R.J., Filip D.J., Rodey G.E., et al. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977, 2:219-226.
52. Vassallo R.R. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients. Immunohematology 2009, 25:119-124.
53. Vassallo R.R., Murphy S. A critical comparison of platelet preparation methods. Curr Opin Hematol 2006, 13:323-330.
54. Blake J.T. On the use of operational research for managing platelet inventory and ordering. Transfusion 2009, 49:396-401.
55. Blake J.T., Heddle N., Hardy M., Barty R. Simplified platelet ordering using shortage and outdate targets. Int J Health Plann Manage 2010, 1:144-156.
56. Ni H., Chen P., Spring C.M., et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood 2006, 107:2976-2983.
57. Yang H., Reheman A., Chen P., et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006, 4:2230-2237.
58. Yang H., Lang S., Zhai Z., et al. Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood 2009, 114:425-436.
59. Chen P., Li C., Lang S., et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood 2010, 116:3660-3668.
60. Li C., Piran S., Chen P., et al. The maternal immune response to fetal platelet GPIbalpha causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest 2011, 121:4537-4547.
61. Li C., Li J., Li Y., et al. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol 2012, 2012:384685.
62. McMorran B.J., Marshall V.M., de Graaf C., et al. Platelets kill intraerythrocytic malarial parasites and mediate survival to infection. Science 2009, 323:797-800.
63. Battinelli E.M., Markens B.A., Italiano J.E. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011, 118:1359-1369.
64. Ho-Tin-Noe B., Goerge T., Wagner D.D. Platelets: guardians of tumor vasculature. Cancer Res 2009, 69:5623-5626.
65. Podrez E.A., Byzova T.V., Febbraio M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007, 13:1086-1095.
66. Murphy A.J., Bijl N., Yvan-Charvet L., et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013, 19:586-594.
67. Thon J.N., Schubert P., Duguay M., et al. Comprehensive proteomic analysis of protein changes during platelet storage requires complementary proteomic approaches. Transfusion 2008, 48:425-435.
68. Modery-Pawlowski C.L., Tian L.L., Pan V., et al. Approaches to synthetic platelet analogs. Biomaterials 2013, 34:526-541.
69. Coller B.S., Springer K.T., Beer J.H., et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 1992, 89:546-555.
70. Rybak M.E., Renzulli L.A. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomater Artif Cells Immobilization Biotechnol 1993, 21:101-118.
71. Levi M., Friederich P.W., Middleton S., et al. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nat Med 1999, 5:107-111.
72. Nishiya T., Kainoh M., Murata M., et al. Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia/IIa and Ib alpha under flow conditions: specific synergy of receptor-ligand interactions. Blood 2002, 100:136-142.
73. Ikeda Y., Handa M., Murata M., et al. A new approach to antiplatelet therapy: inhibitor of GPIb/V/IX-vWF interaction. Haemostasis 2000, 30(Suppl 3):44-52.
74. Bertram J.P., Williams C.A., Robinson R., et al. Intravenous hemostat: nanotechnology to halt bleeding. Sci Transl Med 2009, 1:1-8. 11ra22.
75. Ravikumar M., Modery C.L., Wong T.L., et al. Peptide-decorated liposomes promote arrest and aggregation of activated platelets under flow on vascular injury relevant protein surfaces in vitro. Biomacromolecules 2012, 13:1495-1502.
76. Modery-Pawlowski C.L., Tian L.L., Ravikumar M., et al. In vitro and in vivo hemostatic capabilities of a functionally integrated platelet-mimetic liposomal nanoconstruct. Biomaterials 2013, 34:3031-3041.
77. Decuzzi P., Lee S., Bhushan B., et al. A theoretical model for the margination of particles within blood vessels. Ann Biomed Eng 2005, 33:179-190.
78. Modery-Pawlowski C.L., Kuo H.H., Baldwin W.M., et al. A platelet-inspired paradigm for nanomedicine targeted to multiple diseases. Nanomedicine (Lond) 2013, 8:1709-1727.
79. Devine D.V., Serrano K. The platelet storage lesion. Clin Lab Med 2010, 30:475-487.
80. Arnold D.M., Heddle N.M., Kulczycky M., et al. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion 2006, 46:257-264.
81. Heddle N.M., Arnold D.M., Boye D., et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008, 48:1447-1458.
82. Andreu G., Vasse J., Sandid I., et al. Use of random versus apheresis platelet concentrates. Transfus Clin Biol 2007, 14:514-521.
83. Saunders C., Rowe G., Wilkins K., et al. Impact of glucose and acetate on the characteristics of the platelet storage lesion in platelets suspended in additive solutions with minimal plasma. Vox Sang 2013, 105:1-10.
84. Ringwald J., Althoff F., Zimmermann R., et al. Washing platelets with new additive solutions: aspects on the in vitro quality after 48 hours of storage. Transfusion 2006, 46:236-243.
85. van der Meer P.F., Kerkhoffs J.L., Curvers J., et al. In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system. Vox Sang 2010, 98:517-524.
86. Thon J.N., Devine D.V. Translation of glycoprotein IIIa in stored blood platelets. Transfusion 2007, 47:2260-2270.
87. Zimmerman G.A., Weyrich A.S. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008, 28:s17-s24.
88. Schubert P., Culibrk B., Karwal S., et al. Optimization of platelet concentrate quality: application of proteomic technologies to donor management. J Proteomics 2012, 76:329-336. [Spec No.].
89. Jones C.I., Garner S.F., Angenent W., et al. Mapping the platelet profile for functional genomic studies and demonstration of the effect size of the GP6 locus. J Thromb Haemost 2007, 5:1756-1765.
90. Jones C.I., Bray S., Garner S.F., et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood 2009, 114:1405-1416.
91. Garner S.F., Jones C.I., Stephens J., et al. Apheresis donors and platelet function: inherent platelet responsiveness influences platelet quality. Transfusion 2008, 48:673-680.
92. AuBuchon J.P., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005, 45:1335-1341.
93. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004, 104:1534-1541.
94. van Rhenen D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
95. Schubert P., Coupland D., Culibrk B., et al. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment. Transfusion 2013, 53:3164-3173.